MOTS vs. SINT, BJDX, BTTX, ACORQ, AMPE, APVO, SMFL, ALLR, NVTA, and ATHX
Should you be buying Motus GI stock or one of its competitors? The main competitors of Motus GI include Sintx Technologies (SINT), Bluejay Diagnostics (BJDX), Better Therapeutics (BTTX), Acorda Therapeutics (ACORQ), Ampio Pharmaceuticals (AMPE), Aptevo Therapeutics (APVO), Smart for Life (SMFL), Allarity Therapeutics (ALLR), Invitae (NVTA), and Athersys (ATHX). These companies are all part of the "medical" sector.
Sintx Technologies (NASDAQ:SINT) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.
18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 0.8% of Sintx Technologies shares are owned by company insiders. Comparatively, 1.6% of Motus GI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Sintx Technologies has a net margin of -314.39% compared to Sintx Technologies' net margin of -4,033.54%. Sintx Technologies' return on equity of 0.00% beat Motus GI's return on equity.
Motus GI received 127 more outperform votes than Sintx Technologies when rated by MarketBeat users. Likewise, 65.73% of users gave Motus GI an outperform vote while only 61.02% of users gave Sintx Technologies an outperform vote.
Sintx Technologies has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
In the previous week, Motus GI's average media sentiment score of 0.00 equaled Sintx Technologies'average media sentiment score.
Sintx Technologies has higher revenue and earnings than Motus GI. Sintx Technologies is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Motus GI has a consensus target price of $28.88, indicating a potential upside of 37,400.00%. Given Sintx Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Motus GI is more favorable than Sintx Technologies.
Summary
Motus GI beats Sintx Technologies on 10 of the 16 factors compared between the two stocks.
Get Motus GI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Motus GI Competitors List
Related Companies and Tools
